Infectious Disease epidemiology, viral hepatitis, HIV, hard-to-reach populations, vaccines, prevention science, implementation science, drug use, sex work, international public health, capacity building, ethics in human subjects research
antimicrobial resistance; antimicrobial stewardship; Infective Endocarditis; sepsis and septic shock; CIED infection; multidrug-resistant Enterobacterales; cardiavascular infections; Acinetobacter baumannii infections
Arti Rai, Elvin R. Latty Professor of Law and Faculty Director, The Center for Innovation Policy at Duke Law, is an internationally recognized expert in intellectual property (IP) law, innovation policy, administrative law, and health law.
Rai's extensive research on these subjects has been funded by NIH, NSF, Arnold Ventures, the Kauffman Foundation, the Greenwall Foundation, and the Woodrow Wilson Center. Her numerous publications have appeared in both peer-reviewed journals and law reviews. Peer-reviewed journals include Science, the New England Journal of Medicine, JAMA, the Journal of Legal Studies, Nature Biotechnology, and the Journal of Law and the Biosciences.
From March to December 2021, Rai served as Senior Advisor on innovation law and policy issues to the Department of Commerce’s Office of General Counsel. She also regularly advises other federal and state agencies as well as Congress on these issues. She is a member of multiple distinguished councils, including the National Academies’ Forum on Drug Discovery, Development, and Translation, the Polaris Advisory Council to the Government Accountability Office, and the American Law Institute. She has also served as a member of the National Advisory Council for Human Genome Research, as a public member of the Administrative Conference of the United States, and on numerous National Academies committees.
From 2009-2010, Rai headed the Office of Policy and International Affairs at the U.S. Patent and Trademark Office (USPTO). In that capacity, she led policy analysis of the patent reform legislation that ultimately became the America Invents Act and worked to establish the USPTO’s Office of the Chief Economist. Prior to entering academia, Rai clerked in the Northern District of California and was a litigator at Jenner & Block and the Department of Justice.
Rai graduated from Harvard College, magna cum laude, with a degree in biochemistry and history (history and science), attended Harvard Medical School for the 1987-1988 academic year, and received her J.D., cum laude, from Harvard Law School in 1991.
Dr. Paul Turner is the Rachel Carson Professor of Ecology and Evolutionary Biology at Yale University, and Microbiology faculty member at Yale School of Medicine. He obtained a BA in Biology (1988) from University of Rochester, a PhD in Microbial Evolution (1995) from Michigan State University, and did postdocs at National Institutes of Health, University of Valencia in Spain, and University of Maryland-College Park, before joining Yale in 2001. Dr. Turner studies evolutionary genetics of viruses, particularly phages that infect bacterial pathogens and RNA viruses transmitted by arthropods, and researches the use of phages to treat antibiotic-resistant bacterial diseases. He is very active in science-communication outreach to the general public, and is involved in programs where faculty collaborate with K-12 teachers to improve STEMM education in underserved public schools. Dr. Turner’s service includes the National Science Foundation’s Bio Advisory Committee, and his honors include Fellowship in the National Academy of Sciences, American Academy of Arts & Sciences, and American Academy of Microbiology.
I cofounded and helped establish a group called TAILOR (Tailored Antibacterials and Innovative Laboratories for Phage Research) at Baylor College of Medicine in Houston, Texas, as a not-for-profit service center to source and prepare phages for patients with serious, drug-resistant infections. Since there are no approved phage drugs for infections by the U.S. Food and Drug Administration (FDA), the expanded access pathway is used for individual treatments via granting of approval through an investigational New Drug (IND) application. Thus far, TAILOR and its clinical partners in different institutions across the U.S. have worked together to treat a total of 12 patients using this pathway.
Now I am working at KU Leuven in Belgium as a researcher in Laboratory of Gene Technology. I am hoping to bring phage therapeutics to more people across the world in this position as well as solve scientific problems in the implementation of phage therapy.
What is unique about Belgium is its regulatory framework. Phages can be delivered in the form of Magistral preparations (compounding pharmacy preparations in the U.S.) to the patient upon prescription by the treating surgeon. The active pharmaceutical ingredient (API)—the phages, of magistral formulations are prepared according to a monograph. In this way physicians can prescribe the personalized phage preparations while hospital pharmacists prepare and dispense these prescriptions with the API or APIs (as different phage APIs can be combined at the pharmacy).
Dr. Mercedes González Moreno holds a biotechnology degree from the Technical University of Valencia and completed her master’s thesis in the field of biochemical engineering at the Technical University of Berlin. She gained experience in the industrial biotechnology sector at biotechrabbit GmbH before obtaining her Ph.D. at Charité – Universitätsmedizin Berlin, where she also worked as a postdoctoral fellow. Her research focused on improving treatment outcomes for implant-associated infections and developing targeted bacteriophage therapy for drug-resistant bacterial infections. She is currently part of the management team of INCATE, aiming to contribute her expertise in countering antibiotic resistance and supporting new therapies.
me/cfs
entral nervous system diseases; infections; muscular diseases; post-exertional malaise; virus diseases; Myalgic Encephalomyelitis/Chronic Fatigue Syndrome; diagnosis; health services; care; mHealth; heart rate variability; HRV; ME/CFS; myalgic encephalomyelitis; chronic fatigue syndrome; gender differences; fatigue; melatonin; quality of life; sleep quality; zinc; coenzyme Q10; mitochondria; nonrestorative sleep; NADH; C1q; complement system; blood analytics; symptoms; cluster analysis; immunity; dysbiosis; COVID-19; hormone; depression; genetics; miRNAs; therapy; diagnosis.; me/cfs; PPG signals; PPG device; cardiovascular diseases; mathematical analysis; Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS); platelets; fibrinaloid microclots; hypercoagulability; SARS-CoV-2; spike protein; platelet; CoQ10; oxidative stress
me/cfs
fatigue syndrome; chronic; exercise; hypoacetylation; methylhistidine; histone deacetylation; me/cfs; tryptophan metabolism; indoleamine-2; 3-dioxygenase; bistability; kynurenine pathway; substrate inhibition; myalgic encephalomyelitis; chronic fatigue syndrome; mathematical model; critical point; multiple chemical sensitivity; genetic background role; ADORA2A polymorphims; ADORA2A expression; PBMC; inflammatory cytokines; case-control investigation; mitochondria; complex V; TORC1; Seahorse respirometry; biomarker; diagnosis; ME/CFS; ADORA2A SNP; ADORA2A gene expression; autonomic; chronic fatigue; quality of life; Myalgic encephalomyelitis/chronic fatigue syndrome - Post-exertional malaise – Warning signal – Prevention.; Myalgic Encephalomyelitis; Chronic Fatigue Syndrome; C1q; complement system; blood analyt-ics; symptoms; cluster analysis.; ME/CFS = myalgic encephalomyelitis/ chronic fatigue syndrome; PASC = Post-acute sequalae of COVID-19; EBV = Epstein-Barr virus; HHV6 = Human Herpesvirus 6; HIV = human immunodeficiency virus; Mφ = Macrophage; COVID-19= Coronavirus disease 2019; IFNγ; Microglia; CD4+ and CD8+ T cells; Mitochondria.; COVID-19; Case Definition; Long COVID; mitochondrial dysfunction; HIV; AIDS; CD4+T-lymphocytes.; Sex differences; transcriptomics; Autoantibodies; Immunoadsorption; SF-36; Physical Function; GPCR-Antibodies; Post-COVID Syndrome; Myalgic Encephalomyelitis/Chronic Fatigue Syndrome; Long Covid; : Long COVID; Criteria; GWAS; rs17713054; rs7949972; rs61882275; rs12610495; gene-gene interactions; gene-environmental interactions; coronary artery disease; stroke; FM; TTMV; Anellovirus; Betatorquetevirus family; microarray
Myalgic Encephalomyelitis/Chronic Fatigue Syndrome; immunoadsorption; ß2 adrenoreceptor autoantibody; chronic fatigue syndrome; myalgic encephalomyelitis; autoimmunity; immunology; IgG replacement; IgG deficiency; biomarker; adrenergic receptors; autoantibodies; vasoregulation; G-protein-coupled receptor; me/cfs; ME/CFS; SF-36; physical function; long COVID; GPCR-antibodies; post-COVID syndrome; post-viral syndrome; registry; post-COVID; PASC; children; adolescents
ME/CFS; QoL; family impact; FROM-16; WHOQOL-BREF; education; medical school; teaching; patient safety; NICE Guidelines; Health Act 1983; General Medical Council; GMC; Medical Schools Council; MSC; long Covid; me/cfs; qol; from-16; QOL; myalgic encephalomyelitis; chronic fatigue syndrome; quality of life
hronic fatigue syndrome; myalgic encephalomyelitis; autoimmunity; immunology; IgG replacement; IgG deficiency; biomarker; adrenergic receptors; autoantibodies; vasoregulation; G-protein-coupled receptor; endothelial cells; angiogenesis; endothelial dysfunction; post-COVID syndrome; myalgic encephalomyelitis/chronic fatigue syndrome; Autoantibodies; me/cfs; ME/CFS; Chronic Fatigue Syndrome; Biomarker; hand grip strength; COVID-19; post-viral syndrome; registry; post-COVID; PASC; children; adolescents; Myalgic Encephalomyelitis
Clostridium difficile; Clostridioides difficile; C. difficile infection; bezlotoxumab; recurrence; long-COVID; immunological alterations; corticosteroids; phage therapy; bacteriophages; endolysins; antimicrobial resistance; compassionate use; drug regulation; COVID-19-associated pulmonary aspergillosis (CAPA); pulmonary aspergillosis; antifungal; infections; Infections; INFECTIONS; antiviral; remdesivir; post-COVID-19